Display options
Cite
McPherson SM, Burduli E, Smith CL, et al. A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Subst Abuse Rehabil. 2018;9:43-57doi: 10.2147/SAR.S138439.
McPherson, S. M., Burduli, E., Smith, C. L., Herron, J., Oluwoye, O., Hirchak, K., Orr, M. F., McDonell, M. G., & Roll, J. M. (2018). A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Substance abuse and rehabilitation, 943-57. https://doi.org/10.2147/SAR.S138439
McPherson, Sterling M, et al. "A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies." Substance abuse and rehabilitation vol. 9 (2018): 43-57. doi: https://doi.org/10.2147/SAR.S138439
McPherson SM, Burduli E, Smith CL, Herron J, Oluwoye O, Hirchak K, Orr MF, McDonell MG, Roll JM. A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies. Subst Abuse Rehabil. 2018 Aug 13;9:43-57. doi: 10.2147/SAR.S138439. eCollection 2018. PMID: 30147392; PMCID: PMC6095117.
Copy Download .nbib Format: NLM
Share it on

Subst Abuse Rehabil. 2018 Aug 13;9:43-57. doi: 10.2147/SAR.S138439. eCollection 2018.

A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies.

Substance abuse and rehabilitation

Sterling M McPherson, Ekaterina Burduli, Crystal Lederhos Smith, Jalene Herron, Oladunni Oluwoye, Katherine Hirchak, Michael F Orr, Michael G McDonell, John M Roll

Affiliations

  1. Department of Medical Education and Clinical Sciences, Elson S Floyd College of Medicine, Washington State University, [email protected].
  2. Programs of Excellence in Addictions Research, Washington State University, [email protected].
  3. Analytics and Psychopharmacology Laboratory (APPL), Washington State University, [email protected].
  4. Translational Addictions Research Center, Washington State University, [email protected].
  5. College of Nursing, Washington State University.
  6. Behavioral Health Interventions (BHI), Washington State University, Spokane, WA, USA.

PMID: 30147392 PMCID: PMC6095117 DOI: 10.2147/SAR.S138439

Abstract

This review of contingency management (CM; the behavior-modification method of providing reinforcement in exchange for objective evidence of a desired behavior) for the treatment of substance-use disorders (SUDs) begins by describing the origins of CM and how it has come to be most commonly used during the treatment of SUDs. Our core objective is to review, describe, and discuss three ongoing critical advancements in CM. We review key emerging areas wherein CM will likely have an impact. In total, we qualitatively reviewed 31 studies in a systematic fashion after searching PubMed and Google Scholar. We then describe and highlight CM investigations across three broad themes: adapting CM for underserved populations, CM with experimental technologies, and optimizing CM for personalized interventions. Technological innovations that allow for mobile delivery of reinforcers in exchange for objective evidence of a desired behavior will likely expand the possible applications of CM throughout the SUD-treatment domain and into therapeutically related areas (eg, serious mental illness). When this mobile technology is coupled with new, easy-to-utilize biomarkers, the adaptation for individual goal setting and delivery of CM-based SUD treatment in hard-to-reach places (eg, rural locations) can have a sustained impact on communities most affected by these disorders. In conclusion, there is still much to be done, not only technologically but also in convincing policy makers to adopt this well-established, cost-effective, and evidence-based method of behavior modification.

Keywords: contingency management; drug- and alcohol-use biomarkers; novel substance-use treatment technologies; substance-use disorder treatment

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. Am J Addict. 2000 Spring;9(2):113-25 - PubMed
  2. J Subst Abuse Treat. 2010 Oct;39(3):255-63 - PubMed
  3. Drug Alcohol Depend. 2003 Sep 10;71(3):281-94 - PubMed
  4. Ann Pharmacother. 2003 May;37(5):625-30 - PubMed
  5. Int J Ment Health Addict. 2018 Jun;16(3):672-679 - PubMed
  6. Addiction. 2000 Sep;95(9):1335-49 - PubMed
  7. Community Ment Health J. 2011 Apr;47(2):227-32 - PubMed
  8. Arch Gen Psychiatry. 2006 Apr;63(4):426-32 - PubMed
  9. J Consult Clin Psychol. 2000 Feb;68(1):64-72 - PubMed
  10. J Consult Clin Psychol. 2008 Dec;76(6):1076-82 - PubMed
  11. Drug Alcohol Depend. 2015 Dec 1;157:184-7 - PubMed
  12. Am J Addict. 2010 Nov-Dec;19(6):496-503 - PubMed
  13. Prev Med. 2012 Nov;55 Suppl:S86-94 - PubMed
  14. Drug Alcohol Depend. 2007 Apr 17;88(1):54-63 - PubMed
  15. Psychiatr Serv. 2004 Apr;55(4):445-7 - PubMed
  16. IEEE Trans Biomed Eng. 2011 Jun;58(6):1724-33 - PubMed
  17. Addiction. 2006 Nov;101(11):1546-60 - PubMed
  18. J Anal Toxicol. 2013 Sep;37(7):430-2 - PubMed
  19. Addict Behav. 2013 Sep;38(9):2455-62 - PubMed
  20. Drug Alcohol Depend. 2011 Nov 1;118(2-3):391-9 - PubMed
  21. J Appl Behav Anal. 2016 Dec;49(4):947-953 - PubMed
  22. Psychol Rep. 1971 Apr;28(2):575-80 - PubMed
  23. Arch Gen Psychiatry. 1994 Jul;51(7):568-76 - PubMed
  24. Psychol Addict Behav. 2003 Sep;17(3):249-51 - PubMed
  25. Transl Issues Psychol Sci. 2016 Jun;2(2):128-152 - PubMed
  26. Science. 2004 Oct 15;306(5695):503-7 - PubMed
  27. Psychol Addict Behav. 2009 Mar;23(1):168-74 - PubMed
  28. J Nerv Ment Dis. 1971 Dec;153(6):434-44 - PubMed
  29. Int J Addict. 1978 Jul;13(5):737-46 - PubMed
  30. Drug Alcohol Depend. 2015 Aug 1;153:293-9 - PubMed
  31. Am J Psychiatry. 2017 Apr 1;174(4):370-377 - PubMed
  32. Drug Alcohol Depend. 2013 Jul 1;131(1-2):162-5 - PubMed
  33. Am J Addict. 2014 Jan-Feb;23(1):15-20 - PubMed
  34. Drug Alcohol Depend. 2007 Mar 16;87(2-3):175-82 - PubMed
  35. J Consult Clin Psychol. 2008 Aug;76(4):556-67 - PubMed
  36. J Subst Abuse Treat. 1997 Jul-Aug;14(4):333-7 - PubMed
  37. Addiction. 2007 Apr;102 Suppl 1:114-20 - PubMed
  38. Am J Addict. 2014 Jul-Aug;23(4):407-10 - PubMed
  39. Int J Epidemiol. 2007 Aug;36(4):758-60 - PubMed
  40. Drug Alcohol Depend. 2002 Jan 1;65(2):179-89 - PubMed
  41. Drug Alcohol Depend. 2017 Sep 1;178:417-424 - PubMed
  42. Addict Behav. 2007 Jun;32(6):1220-36 - PubMed
  43. Am J Addict. 2014 May-Jun;23(3):205-10 - PubMed
  44. Exp Clin Psychopharmacol. 2012 Aug;20(4):287-92 - PubMed
  45. Addiction. 2006 Feb;101(2):192-203 - PubMed
  46. Disabil Rehabil. 2003 May 20;25(10):549-60 - PubMed
  47. Exp Clin Psychopharmacol. 2000 Aug;8(3):377-86 - PubMed
  48. Drug Alcohol Depend. 1986 Jul;17(4):311-22 - PubMed
  49. Addiction. 2013 May;108(5):900-9 - PubMed
  50. Am J Psychiatry. 2008 Feb;165(2):179-87 - PubMed
  51. Drug Alcohol Depend. 2013 Feb 1;128(1-2):71-6 - PubMed
  52. J Dual Diagn. 2014;10(3):108-17 - PubMed
  53. Psychol Addict Behav. 2016 Aug;30(5):536-543 - PubMed
  54. J Subst Abuse Treat. 2011 Jan;40(1):87-94 - PubMed
  55. Alcohol Clin Exp Res. 2003 Nov;27(11):1785-97 - PubMed
  56. Drug Alcohol Depend. 2010 Dec 1;112(3):247-50 - PubMed
  57. J Consult Clin Psychol. 2010 Feb;78(1):62-71 - PubMed
  58. Addiction. 2006 Feb;101(2):267-74 - PubMed
  59. Issues Ment Health Nurs. 2005 Dec;26(10):979-99 - PubMed
  60. Subst Abus. 2010 Jul;31(3):127-35 - PubMed
  61. Nat Neurosci. 2005 Nov;8(11):1458-63 - PubMed
  62. Addiction. 2007 Sep;102(9):1443-53 - PubMed
  63. Drug Alcohol Depend. 2004 Dec 7;76(3):247-59 - PubMed
  64. Alcohol Res Health. 1999;23(2):122-7 - PubMed
  65. Contemp Clin Trials. 2016 Mar;47:93-100 - PubMed
  66. Exp Clin Psychopharmacol. 2005 May;13(2):83-92 - PubMed
  67. Arch Gen Psychiatry. 2005 Oct;62(10):1148-56 - PubMed
  68. J Subst Abuse Treat. 2010 Oct;39(3):202-9 - PubMed
  69. Am J Addict. 2007 Nov-Dec;16(6):457-60 - PubMed
  70. Psychol Addict Behav. 2015 Sep;29(3):501-11 - PubMed
  71. Am J Psychiatry. 2013 Jan;170(1):94-101 - PubMed
  72. Clin Trials. 2012 Dec;9(6):689-95 - PubMed
  73. J Consult Clin Psychol. 2000 Dec;68(6):1051-61 - PubMed
  74. J Subst Abuse Treat. 2016 Feb;61:18-25 - PubMed
  75. J Appl Behav Anal. 1986 Summer;19(2):197-202 - PubMed
  76. Drug Alcohol Depend. 2002 Jul 1;67(2):125-37 - PubMed
  77. J Clin Psychiatry. 2014 Apr;75(4):336-43 - PubMed
  78. Drug Alcohol Depend. 2009 Jun 1;102(1-3):108-15 - PubMed
  79. Addiction. 2017 May;112(5):875-883 - PubMed
  80. Psychol Rec. 2015 Jun 1;65(2):347-353 - PubMed
  81. Annu Rev Psychol. 2004;55:431-61 - PubMed
  82. Subst Abus. 2007 Mar;28(1):31-44 - PubMed
  83. BMJ. 2007 Jul 28;335(7612):203-5 - PubMed
  84. Arch Gen Psychiatry. 2006 Feb;63(2):201-8 - PubMed
  85. Drug Alcohol Depend. 2006 Oct 15;85(1):19-27 - PubMed
  86. Clin Psychol Rev. 2010 Feb;30(1):12-24 - PubMed
  87. Innov Clin Neurosci. 2016 Oct 01;13(9-10):12-19 - PubMed
  88. Pharmacol Ther. 2005 Oct;108(1):119-28 - PubMed
  89. J Subst Abuse Treat. 2005 Jan;28(1):57-65 - PubMed
  90. Drug Alcohol Depend. 2016 Mar 1;160:65-75 - PubMed
  91. Alcohol Clin Exp Res. 2015 May;39(5):905-10 - PubMed
  92. NIDA Res Monogr. 1979 Jun;(25):68-90 - PubMed
  93. Exp Clin Psychopharmacol. 2015 Dec;23(6):486-93 - PubMed
  94. J Subst Abuse Treat. 2015 Feb;49:58-64 - PubMed

Publication Types

Grant support